Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development by To, Kwong-Him et al.
RESEARCH ARTICLE Open Access
Regulation of p14
ARF expression by miR-24:
a potential mechanism compromising the p53
response during retinoblastoma development
Kwong-Him To
1,2,3, Sanja Pajovic
1, Brenda L Gallie
1,2,3,4,5 and Brigitte L Thériault
1,6*
Abstract
Background: Most human cancers show inactivation of both pRB- and p53-pathways. While retinoblastomas are
initiated by loss of the RB1 tumor suppressor gene, TP53 mutations have not been found. High expression of the
p53-antagonist MDM2 in human retinoblastomas may compromise p53 tumor surveillance so that TP53 mutations
are not selected for in retinoblastoma tumorigenesis. We previously showed that p14
ARF protein, which activates
p53 by inhibiting MDM2, is low in retinoblastomas despite high mRNA expression.
Methods: In human fetal retinas, adult retinas, and retinoblastoma cells, we determined endogenous p14
ARF mRNA,
ARF protein, and miR-24 expression, while integrity of p53 signalling in WERI-Rb1 cells was tested using an
adenovirus vector expressing p14
ARF. To study p14
ARF biogenesis, retinoblastoma cells were treated with the
proteasome inhibitor, MG132, and siRNA against miR-24.
Results: In human retinoblastoma cell lines, p14
ARF mRNA was disproportionally high relative to the level of p14
ARF
protein expression, suggesting a perturbation of p14
ARF regulation. When p14
ARF was over-expressed by an
adenovirus vector, expression of p53 and downstream targets increased and cell growth was inhibited indicating
an intact p14
ARF-p53 axis. To investigate the discrepancy between p14
ARF mRNA and protein in retinoblastoma, we
examined p14
ARF biogenesis. The proteasome inhibitor, MG132, did not cause p14
ARF accumulation, although
p14
ARF normally is degraded by proteasomes. miR-24, a microRNA that represses p14
ARF expression, is expressed in
retinoblastoma cell lines and correlates with lower protein expression when compared to other cell lines with high
p14
ARF mRNA. Transient over-expression of siRNA against miR-24 led to elevated p14
ARF protein in retinoblastoma
cells.
Conclusions: In retinoblastoma cells where high levels of p14
ARF mRNA are not accompanied by high p14
ARF
protein, we found a correlation between miR-24 expression and low p14
ARF protein. p14
ARF protein levels were
restored without change in mRNA abundance upon miR-24 inhibition suggesting that miR-24 could functionally
repress expression, effectively blocking p53 tumor surveillance. During retinal tumorigenesis, miR-24 may
intrinsically compromise the p53 response to RB1 loss.
Background
Retinoblastoma is initiated by inactivation of both RB1
alleles encoding the protein, pRB that controls cell pro-
liferation, differentiation and genomic stability. Persons
heterozygous for a germline RB1 mutation are predis-
posed to cancer of the developing retina with a rate and
penetrance unmatched in any other tissue. The unique
sensitivity of developing retina to RB1 loss may be
explained by an inability to trigger protective tumor
suppressor pathways readily activated in other tissues.
As a safeguard against loss of pRB, cells generally
respond by activating the potent tumor suppressor gene
TP53 that induces apoptosis and cell cycle arrest [1].
p53 is tightly regulated by MDM2 and MDM4 through
proteolysis and suppression of transactivating activity,
respectively [2]. Crosstalk between the pRB and p53
pathways is mediated by p14
ARF (referred to as ARF
hereafter). Loss of pRB specifically activates E2F1 to
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element that has activity in various tumor cells with
defective pRB, but not in normally growing cells [3].
Once activated, ARF inhibits MDM2, leading to p53 sta-
bilization and transcription of p53 target genes [4-6].
Concurrent inactivation of the pRB and p53 pathways
is a hallmark of cancer. However in retinoblastoma,
TP53 mutation has not been reported, and alternative
modes of p53 inactivation implicating MDM2 and
MDM4 have been suggested but remain to be con-
firmed, since the expression of MDM2 in retinoblasto-
mas is similar to retina [7-9] and MDM4 is situated in a
region of frequent genomic gain (chromosome 1q32)
that also contains the oncogene KIF14 [10]. In addition,
it has been suggested that retinoblastoma arises from a
retinal cell that naturally expresses high level MDM2,
thereby bypassing the requirement for p53 genetic inac-
tivation [8].
We previously observed low ARF protein in retino-
blastoma cell lines despite robust mRNA expression,
suggesting protein instability or translational attenuation
of ARF [7]. We now demonstrate repression of ARF
expression by miR-24 in retinoblastoma that may effec-
tively block activation of p53 tumor surveillance in
response to RB1 loss.
Methods
Tissue culture
Cell lines were grown in a humidified 37°C incubator
with 5% CO2 in their respective media with 100 U/ml
penicillin and 0.1 mg/ml streptomycin (Wisent Biopro-
ducts). Retinoblastoma cell lines with characterized RB1
mutations ([11,12] and manuscript in preparation) were
g r o w ni nI s c o v e ’s MDM (Invitrogen) with 15% Fetal-
Clone III (HyClone), 10 mg/L insulin (Sigma-Aldrich)
and 0.0004% (v/v) b-mercaptoethanol. HEK-293, HEK-
293T (HEK-T), SKOV3 and HeLa were grown in
DMEM-H16 with 10% FBS (Wisent Bioproducts). SaOS-
2 were grown in DMEM-H21 with 10% FBS. OVCAR-3
was grown in RPMI-1640 with 20% FBS and 10 mg/L
insulin. To study proteasome-mediated protein degrada-
tion, cells were incubated in 50 μM MG132 (Sigma-
Aldrich) for 10 hours.
RT-PCR
Total RNA was extracted using TRIzol (Invitrogen)
according to manufacturer’s instructions. RNA concen-
tration and quality were determined using a Nanodrop-
1000 spectrophotometer (Thermo Scientific). For cDNA
synthesis, 1 μg of total RNA was reverse transcribed
using random primers (Invitrogen) and Superscript II
Reverse Transcriptase (Invitrogen). For gene expression
analysis, PCR was performed using a RoboCycler Gradi-
ent 96 thermal cycler (Stratagene). PCR began with 2
minutes at 94°C, followed by 35 cycles of amplification,
ending with 10 minutes at 72°C, in reaction mixture
including 200 μMd N T P s ,2 . 5m MM g C l 2,0 . 5μM each
of forward and reverse primers, 0.5 U Hot start DNA
polymerase (Fermentas), 1× PCR buffer (Novagen) and
1 μl of cDNA product with a final volume of 25 μl.
Quantitative real-time PCR
RNA extraction and cDNA synthesis were performed as
described above. Real-time PCR was performed in a
7900HT Fast Real-Time PCR system using Universal
PCR Master Mix in 384-well plates (Applied Biosys-
tems). Taqman gene expression assays (Applied Biosys-
tems) were employed to measure mRNA expression of
ARF (Hs99999189_m1) and GAPDH (Hs99999905_m1)
in triplicate. Mean relative gene expression and standard
deviation were determined using the ΔΔCt method
built-in to the SDS 2.2 software (Applied Biosystems).
GAPDH was the endogenous control gene; fetal retina
was the calibrator sample. Total RNA from fetal retina
(pooled 16.5 and 17 weeks) was a kind gift from Dr.
Rod Bremner, Toronto Western Research Institute, Tor-
onto, ON. Adult retina (HR 50 and 108) was obtained
from the enucleated eyes of cornea donors provided by
the Eye Bank of Canada, with the University Health
Network Research Ethics Board (REB) approval for
anonymous use of discarded specimens.
Western blot
Cell lines were dissociated mechanically in lysis buffer
(phosphate buffered saline, 1% Nonidet P40, 5% sodium
deoxycholate, 0.1% SDS, 1.0 μg/ml leupeptin, 0.1 mM
PMSF, 1.0 μg/ml aproptinin and 100 μM sodium ortho-
vanadate), lysed by three freeze-thaw cycles, incubated
on ice for 30 minutes, and centrifuged to remove cellu-
lar debris. Protein lysates from human fetal (pooled 16.5
and 17 weeks) retinas were kindly provided by Dr. Rod
Bremner. Adult retinas were provided by the Eye Bank
of Canada and total protein lysates isolated as above.
Protein concentration was determined using BioRad
Protein Assay (BioRad). For SDS-PAGE, 50 μgo fp r o -
tein lysate was resolved in 4-20% Tris-Glycine gradient
gels (Lonza) and transferred onto PVDF (BioRad) mem-
branes. Membrane was blocked in 5% blotto (BioRad) in
TBS overnight at 4°C and subsequently probed with pri-
mary antibody in TBS with 1% BSA and 0.05% Tween-
20 at room temperature for one hour, followed by three
washes in TBS with 0.1% BSA and 0.05% Tween-20. Pri-
mary antibodies and the respective dilutions used are as
follows: ARF (1:500, 4 C6/4 clone, Cell Signaling Tech-
nologies, #2407 [13]), p21 (1:200, BD-Pharmingen,
556430), p53 (1:200, Santa Cruz, sc6243-G), BAX (1:200,
Santa Cruz, sc7480), MDM2 (1:200, Calbiochem,
OP115) and b-tubulin (1:1000, Sigma-Aldrich, T0198).
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ondary antibodies at specified dilutions in TBS with 1%
BSA and 0.05% Tween-20 at room temperature for one
hour, followed by three washes. Secondary antibodies were
anti-rabbit-HRP (1:10000, Santa Cruz, sc2004), anti-goat-
HRP (1:10000, Santa Cruz, sc2020) and anti-mouse-AP
(1:10000, Santa Cruz, sc2008). Proteins were detected with
HyGLO Chemilluminescence Detection Reagent (Den-
ville). Proteins probed with AP-conjugated secondary anti-
bodies were detected using NBT/BCIP (Denville).
Immunostaining
Cells grown on a coverslip were incubated in 4% paraf-
ormaldehyde for 15 minutes at room temperature, fol-
lowed by three washes in PBS, then incubated in 5%
Triton-X for 10 minutes at room temperature. Blocking
was performed for 30 minutes at room temperature in
TBS with 10% DAKO Protein Block (DAKO-Cytoma-
tion), 1% BSA and 0.05% Tween-20. Slides were incu-
bated with ARF primary antibody (1:200, Abcam,
ab3642) in TBS with 1% BSA, 0.05% Tween-20 and 10%
Antibody Diluent (DAKO-Cytomation), followed by
three washes in TBS with 0.1% BSA and 0.05% Tween-
20, then incubated with goat biotinylated anti-rabbit IgG
secondary antibodies (1:200, Vector Laboratories, BA-
1000) at room temperature for 1 hour, followed by
three washes. ARF was detected with Streptavidin-
Alexa-594 (Molecular Probes); nuclei were visualized
with DAPI. Slides were mounted with DAKO-Cytoma-
tion Fluorescent Mounting Medium.
Adenoviral-mediated ARF expression
E1/E3 early regions-deleted adenovirus encoding gfp
(adgfp) or human ARF (adARF) [14] controlled by CMV
promoter were kind gifts from Dr. Erik Knudsen (Kim-
mel Cancer Center, PA, USA) and Dr. Ruth Gjerset
(Sidney Kimmel Cancer Center, CA, USA), respectively.
To purify adenovirus, infected HEK-293 cells were
resuspended in PBS with 10% glycerol, and viral parti-
cles were released by three freeze-thaw cycles; cellular
debris was then removed by centrifugation. Viral titer
was determined using QuickTiter Adenovirus Titer
Immunoassay Kit (Cell Biolabs); adenovirus was stored
at -72°C. To assess the effect of ARF overexpression on
gene expression and cell growth, 200,000 WERI-Rb1
cells were seeded in 6-well plates pretreated with poly-
D-lysine (Sigma-Aldrich) and incubated overnight. For
immunostaining, cells were seeded on poly-D-lysine
treated coverslips placed within 6-well plates. After
overnight incubation, cells were rinsed once with PBS
and incubated in 500 μlo fs e r u m - f r e eI s c o v e ’sm e d i a
containing adgfp or adARF at 20 multiplicity of infec-
tion (MOI) for 1 hour in a 37°C incubator with 5%
CO2. Complete growth media (2 ml) was added to each
well and incubated for four days, after which cells were
harvested for gene expression analysis. Cell viability was
determined by trypan blue exclusion (Invitrogen).
Means and standard deviations were based on three
replicates per treatment. Statistical significance was
determined using two-tailed t-test.
miRNA cDNA synthesis and quantitative real-time PCR
Total RNA extraction was performed as described
above. A commercially available miRNA cDNA synthesis
kit (TaqMan
® MicroRNA Reverse Transcription Kit,
Applied Biosystems) was used to reverse transcribe miR-
24 with specific RT primers (TaqMan
® miRNA Assays,
Applied Biosystems). A sequence-specific assay (Taq-
Man
® real-time PCR assays, Applied Biosystems) was
used to detect mature miR-24 from cell extracts.
RNU44, a small non-coding RNA with wide and con-
stant tissue distribution (Applied Biosystems), was used
as the endogenous control.
Anti-miR-24 siRNA
Asychronous WERI-Rb1 cells were transiently trans-
fected with 50 pM of anti-miR-24 siRNA (Ambion, ID:
AM12902) or control siRNA (Ambion, ID: AM17010)
using a WERI-Rb1 cell transfection reagent (Altogen
Biosystems) in serum-free Iscove’s MDM. Cells were
harvested for total protein 72 hours post-transfection
and assayed for ARF and b-tubulin by Western Blot.
Protein quantification
Signal intensity measurements for ARF and b-tubulin
within each sample were calculated via Photoshop CS3.
For each protein sample, the measure of ARF protein
expression (pixel area multiplied by average pixel inten-
sity) was normalized to b-tubulin expression, and then
expressed as relative fold expression in comparison to
normalized fetal retina ARF expression [15].
Results
Low ARF protein to mRNA expression ratios in human
retinoblastoma cell lines
We have previously shown that ARF protein in primary
retinoblastomas and cell lines is low compared to the
level of mRNA [7], suggesting selective regulation of
ARF expression during tumorigenesis. To elaborate on
this finding, ARF expression was compared between
normal human fetal (FR) and adult retinal (HR) tissues,
retinoblastoma cell lines with characterized, non-func-
tional RB1 [11,12] (RB1
-/-), and cell lines known for
high ARF mRNA expression (HeLa, HEK-T, SaOS-2 and
OVCAR-3) or low ARF mRNA (SKOV3). Most RB1
-/-
retinoblastomas (RB 247, 381, 1021, WERI-Rb1, Y79)
expressed high levels of ARF mRNA, some (RB247,
RB381) comparable to that of HeLa (Figure 1A). However,
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Page 3 of 9Figure 1 Expression of ARF in human retinoblastoma cell lines.( A) Comparison of ARF mRNA level between normal human fetal (FR) and
adult retinas (HR 50 and 108), RB1
-/- retinoblastoma cell lines (RB 247, 381, 1021, WERI-Rb1 (WERI), Y79), RB1
+/+ cell lines (RB 3823, 522), and
other cell lines (HeLa, SKOV3, HEK-T, SaOS2, OVCAR3) using quantitative real-time PCR. GAPDH was used as an endogenous control. (B) Western
Blot analysis of ARF in fetal retina (FR), adult retina (HR 50), RB1
-/- retinoblastoma (RB247, 381, 1021, WERI-Rb1 (WERI), Y79), RB1
+/+ retinoblastoma
(RB 3823, 522), and other (HeLa, HEK-293T, OVCAR-3 and SaOS-2) cell lines. *Same cell extracts were added to ensure consistent ARF protein
expression/detection between immunoblots. (C) Ratio of relative ARF protein expression (normalized to b-tubulin, relative to FR) to relative ARF
mRNA (normalized to GAPDH, relative to FR). (D) Confirmation of full length ARF mRNA expression in fetal retina (FR), human retina (HR 50),
retinoblastoma cell lines and other cell lines using RT-PCR.
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+/+:R B
3823, RB 522) had very low levels of ARF mRNA. These
RB1
+/+ retinoblastomas show no detectable mutations in
the RB1 gene and express full-length pRB protein [16]. All
retinoblastomas with the exception of WERI-Rb1
expressed low ARF protein relative to cell lines HeLa,
HEK-T, SaOS2 and OVCAR3 (Figure 1B). The ratio of
ARF protein to mRNA levels (normalized relative to FR)
revealed that some RB1
-/- retinoblastoma cell lines (RB
247, RB 381, RB 1021, WERI-Rb1) demonstrate much
lower ratios of protein:mRNA than both human fetal and
adult retinas, RB1
+/+ cell lines (RB 3823 and 522), and can-
cer cell lines HeLa and SKOV3 (Figure 1C), indicating a
defect in ARF protein translation. Since quantitative RT-
PCR amplifies only 72 base pairs of the full length ARF
mRNA, fragmented mRNA could be detected. RT-PCR
spanning all three ARF exons confirmed the presence of
intact, full length ARF mRNA (Figure 1D).
Intact p53 signalling downstream of ARF
To test if increased ARF can activate p53 and p53-tran-
scriptional targets, adenovirus encoding human ARF
cDNA (adARF) [14,17] was used to drive ARF expres-
sion in the retinoblastoma cell line WERI-Rb1, which
expresses MDM2 and MDM4 [7,9]. After transduction,
normal ARF nucleolar localization was detected as foci
within the nucleus [18] (Figure 2A). AdARF-treated cells
showed accumulation of p53 protein and p53-down-
stream targets p21, MDM2 and BAX (Figure 2B), and
inhibition of cell growth (Figure 2C). Therefore,
enforced expression of ARF activated p53 and p53-tar-
gets, and inhibited tumor cell growth, suggesting that
optimal levels of ARF can activate p53 despite high
MDM2 and MDM4 expression.
Proteasomal degradation does not account for low ARF
protein
ARF turnover is regulated by the ubiquitin-proteasome
pathway through N-terminus ubiquitination [19]. To
determine if ARF is aberrantly degraded by the protea-
some, retinoblastoma cells were treated with the protea-
some inhibitor, MG132. All treated cell lines responded
with p21 accumulation, whose turnover is proteasome-
regulated (Figure 3). Despite MG132 treatment, ARF
remained undetectable in retinoblastoma cell lines com-
pared to untreated HeLa cells. Therefore, aberrant protea-
somal turnover does not account for low ARF protein in
retinoblastoma, suggesting inhibition of ARF translation as
a possible mechanism for low protein:mRNA ratios.
High miR-24/ARF protein ratios in human retinoblastoma
cell lines
The microRNA miR-24 [20], expressed in both normal
retinas and retinoblastomas [17], regulates the 3’
untranslated region of both p16
INK4a and ARF mRNA
[20]. AdARF mRNA did not contain the two potential
miR-24 target sites, which may explain the accumulation
and activity of exogenously-expressed ARF (Figure 2).
Analysis of miR-24 in human fetal and adult retinas, pri-
mary retinoblastoma tumors, retinoblastoma cell lines
and other cell lines revealed the highest miR-24 expres-
sion in human adult retinas, consistent with reports of
elevated miR-24 expression in terminally differentiated
cells [21]. However, fetal retinas show in general higher
levels of miR-24 compared to the average expression of
primary retinoblastomas and retinoblastoma cell lines
(Figure 4A). All RB1
-/- cell lines, in addition to two out
of the 4 primary RB1
-/- retinoblastomas (RB 2133 and
RB 2362) demonstrated higher miR-24 expression than
the RB1
+/+ cell lines (Figure 4A).
To evaluate the potential role of miR-24 expression in
retinoblastoma and other cell lines, miR-24 expression
Figure 2 Effect of exogenous ARF in retinoblastoma cells.( A)
Immunofluorescence (red) staining for ARF protein in the cell line
WERI-Rb1 four days after infection with adenovirus encoding human
ARF cDNA (adARF) or gfp (adgfp). Blue, DAPI stain. (B) Western Blot
analyses of p53 and its transcriptional targets BAX, MDM2 and p21
in cells treated with adARF or adgfp four days after infection. (C)
Relative number of viable cells after four days of treatment with
adgfp or adARF. N = 3, t-test *P < 0.05.
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protein expression (taking into account the protein/
mRNA ratios from Figure 1C). Comparisons of normal-
ized miR-24 expression and ARF protein expression
demonstrates that RB1
-/- cell lines have very high miR-
24 relative to the amount of expressed protein, in com-
parison to RB1
+/+ cell lines with low ARF protein and
miR-24 (RB 3823 and 522; Figure 4A,B and 4C). Other
cell lines with abundant ARF protein (HeLa, HEK-T)
but low miR-24 (Figure 4B and 4C), or high miR-24 and
ARF protein (SKOV3), demonstrate lower miR-24:pro-
tein ratios, suggesting that high miR-24 levels could
functionally regulate ARF protein expression in RB1
-/-
cell lines.
miR-24 suppresses ARF in retinoblastoma cell lines
To further assess the function of miR-24 in RB1
-/- reti-
noblastoma cell lines, we transiently transfected WERI-
Rb1 cells with a small interfering RNA (siRNA) against
miR-24. Knockdown of miR-24 (approximately 50%, Fig-
ure 4D) resulted in increased ARF protein (2.8-fold), but
no change in ARF mRNA (Figure 4E, F &4G). Thus, low
ARF protein in retinoblastomas despite robust mRNA
expression, at least in part, may reflect the presence and
activity of miR-24 to inhibit ARF expression.
Discussion
We demonstrate that most human retinoblastomas in
which RB1 is inactivated (RB1
-/-)s h o wl o wA R Fp r o t e i n
despite high ARF mRNA. In contrast, RB1
+/+ retinoblas-
toma tumors show low ARF mRNA. This data confirms
previous findings [3] and our results in the Rb knockout
mouse (data not shown) that loss of pRB leads to an
increase in ARF mRNA due to transcriptional activation
by E2F1. High ARF mRNA but low ARF protein also
suggests attenuation of synthesis or instability of ARF in
most RB1
-/- retinoblastoma cell lines. For the cell line
Y79, low ARF was at least in part due to low ARF
mRNA. Although Y79 has an RB1
-/- genome, a trun-
cated pRb protein is produced; this may affect its own
transcription and interplay with E2F family members
[22,23].
Through viral overexpression of ARF, we showed in
WERI-Rb1 cells that: i) exogenous ARF protein expres-
sion induces the p53 response even when MDM2 and
MDM4 are expressed; and ii) the ARF-induced p53
response results in a functional decrease in cell viability.
These data demonstrate that the integrity of the p53
pathway is maintained in retinoblastoma cells, and that
ARF protein expression may play an important role in
controlling p53 responses. We have shown that protea-
somal degradation does not account for low ARF pro-
tein in the WERI-Rb1 cell line, thus other mechanisms
of ARF protein regulation may exist. Indeed, miR-24 has
documented expression in normal retinas and retino-
blastomas, and demonstrated translational repression of
p16
INK4a mRNA, which shares 100% homology with the
3’ untranslated region of ARF [20,24,25]. In our expres-
sion analyses, miR-24 is less abundant in human retino-
blastomas than in normal fetal and adult retinas, with
highest expression in adult retinas, consistent with
reports of elevated miR-24 expression in terminally dif-
ferentiated cells [21]. We showed that fetal retinas in
general demonstrate higher miR-24 expression than reti-
noblastoma tumors. This data suggests regulation of
miR-24 expression during retinal development, perhaps
due to its role in regulation of p53 via ARF to suppress
p53 hyperactivation and unwanted cell death. Indeed
miR-24 was shown to be involved in developmental
apoptosis in Xenopus retina [26]. Paradoxically, when
pRB is inactivated during retinal tumorigenesis, ARF
protein regulation mediated by high miR-24 intrinsic
levels may impede the tumor suppressor functions of
p53. Moreover, the pleiotropic miR-24, in addition to its
Figure 3 Role of the proteasome in ARF regulation. Western Blot analysis of ARF and p21 in retinoblastoma cell lines after MG132 treatment.
Retinoblastoma cell lines were treated with the proteasome inhibitor MG132 for 10 hours. p21 was used as a positive control since its
degradation is regulated by the ubiquitin-proteasome pathway.
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Page 6 of 9Figure 4 Role of miR-24 in retinoblastoma ARF regulation.( A) Real-time quantitative PCR analysis of miR-24 expression in human fetal retina
(FR) and adult retina (HR 50 and 108), RB1
-/- retinoblastoma tumors (RB 2133, 2345, 2362, 3103), RB1
-/- retinoblastoma cell lines (RB 247, 381, 383,
1021, WERI-Rb1 (WERI), Y79), RB1
+/+ retinoblastoma cell lines (RB 3823, 522) and other cell lines (HeLa, SKOV3, HEK-T, SaOS2, OVCAR3). N = 3. (B)
Comparison of normalized ARF protein expression (values taken from ARF protein/ARF mRNA expression, as depicted in Figure 1C) to miR-24
expression in human fetal retina (FR), human adult retina (HR 50), RB1
-/- retinoblastoma cell lines (RB 247, 381, 1021, WERI-Rb1 (WERI), Y79), RB1
+/+ retinoblastoma cell lines (RB 3823, 522) and other cell lines (HeLa, SKOV3, HEK-T, SaOS2, OVCAR3). (C) Ratio of miR-24 expression (normalized
to RNU44), relative to normalized ARF protein expression (values taken from ARF protein/ARF mRNA expression, as depicted in Figure 1C). (D)
Quantitative real-time PCR analysis of miR-24 after WERI-Rb1 cells were transiently transfected with anti-miR-24 siRNA or control siRNA for 72
hours, and presented as fold change normalized to RNU44 expression, relative to control siRNA; N = 3, t-test *P < 0.05. (E) Quantitative real-time
PCR analysis of ARF mRNA after anti-miR-24 siRNA or control siRNA transfection, N = 3. (F) ARF expression measured by immunoblot in response
to control siRNA and anti-miR-24 siRNA transient transfection of WERI-Rb1; ARF protein levels in HeLa cells are shown for positive ARF protein
expression. (G) Graph represents fold change in ARF protein in WERI-Rb1 cells normalized to b-tubulin, relative to control siRNA. N = 3, t-test *P
< 0.05.
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of MYC and E2F2 [21], which are important in driving
proliferation and imperative to tumor growth. The
reduced miR-24 level in retinoblastomas relative to nor-
mal retinas may be explained by the requirement of sus-
tained expression of proliferation genes in tumor cells
while maintaining sufficient amounts of miR-24 to
repress the ARF tumor suppressor. Intriguingly, the low
miR-24:protein ratios in RB1
+/+ retinoblastomas are
consistent with the notion that, in the absence of selec-
tion pressure from ARF activation induced by RB1 loss,
tumor cells may maximize proliferation through the
derepression of MYC and E2F2 [21] without the com-
promise of tumor suppressor activation. Thus the
observed miR-24 in retinoblastoma tumors might be at
an optimal level that maximizes tumor cell growth and
survival. Some RB1
-/- primary tumors showed low miR-
24 expression, comparable to RB1
+/+ cell lines. These
“low miR-24” RB1
-/- tumors raise the possibility that the
level of miR-24 expression may be insufficient to com-
promise the p53 response in some retinoblastoma
tumors. However other factors besides expression, such
as components of the RISC complex, may influence the
effect of miR-24 activity in retinoblastoma cells [27].
ARF could also be regulated by other microRNAs in
retinoblastomas. For example, expression of miR-125b
and miR-24 is similar in retinoblastomas [28], and miR-
125b has been shown to regulate the 3’ untranslated
region of p16
INK4a and ARF mRNA [20]. To gain insight
o nt h er o l eo fm i R - 2 4o nt h eA R F - p 5 3a x i s ,at h o r o u g h
examination of the biological and functional implica-
tions of miR-24 expression in human retinal and retino-
blastoma tumor development is thus warranted.
Regulation of ARF protein expression by miR-24 in
retinoblastoma cell lines points to a possible mechanism
through which ARF protein is decreased in retinoblas-
toma cells. We uncovered an intact p53 response in
WERI-Rb1 cells through overexpression of ARF protein;
however, whether targeting miR-24 in retinoblastoma
cells would increase ARF protein expression to optimal
levels to elicit a p53 response remains to be investigated.
Our miR-24 and ARF protein expression data are in
agreement with ARF protein regulation by miR-24 that
is unique to RB1
-/- retinoblastomas. However, SaOS2
and OVCAR3 cell lines show similar miR-24:protein
ratios as RB1
-/- retinoblastoma cell lines, suggesting that
miR-24 regulation of ARF may apply to other cell types.
Given that the other cell lines tested display different
genetic or protein changes to those seen in retinoblas-
toma cell lines, such as wild-type RB1 (SKOV3 and
OVCAR3), inactivated pRb (HeLa and HEK-T) or
mutant TP53 (SKOV3, OVCAR3 and SaOS2) [29,30],
further investigation into the functional mechanisms of
ARF regulation via miR-24 are required. Differential
miR-24:protein ratios between RB1
-/- retinoblastomas,
fetal retina and adult retina, and RB1
+/+ retinoblastomas,
combined with ARF-mediated apoptosis and miR-24-
regulated ARF expression in WERI-Rb1 cells nonethe-
less demonstrate a unique mechanism in RB1
-/- retino-
blastoma tumors through which proliferation could be
maintained by miR-24 suppression of ARF.
Conclusions
Our data indicates that p53-tumor surveillance in
response to RB1 loss may be suboptimal in the develop-
ing retina, not only due to high levels of MDM2 and
MDM4, but inadequate levels of ARF, possibly as a
result of suppression by miR-24. We demonstrated that
exogenous ARF expression activated p53 and its down-
stream targets in retinoblastoma cells, resulting in
reduced proliferation. We suggest that low endogenous
ARF protein may present an innate mechanism that
could regulate p53 functions during retinoblastoma
development.
We propose that the unique retinal sensitivity to
tumorigenesis induced by RB1 loss is primarily due to a
barrier to apoptosis inherent in developing retina, con-
sistent with the demonstration in mice that the cell of
retinoblastoma origin is intrinsically death resistant [31].
This mechanism may facilitate the control of develop-
mental apoptosis to achieve precise numbers of various
cell types in the retina, reflected by high MDM2 expres-
sion in the developing retina [8]. However, when retinal
cells are transformed, high MDM2 expression is consis-
tently expressed, but at variable levels [7]; thus other
factors may affect p53 tumor surveillance. We suggest
that miR-24-mediated repression of ARF, a crucial signal
transducer that bridges loss of pRB to p53-tumor sur-
veillance, may also compromise the proper response to
RB1 inactivation, alleviating the requirement for genetic
abrogation of the p53-pathway during retinoblastoma
development. Our results point to the potential use of
ARF supplementation in the development of therapeutic
approaches targeting p53 activation in retinoblastoma.
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